High-throughput flow cytometry purification of transduced progenitors expressing defined levels of vascular endothelial growth factor induces controlled angiogenesis in vivo

Stem Cells

Volumn 28, Issue 3, 2010, Pages 611-619

  Misteli, Heidi ^a   Wolff, Thomas ^a   Füglistaler, Philipp ^a   Gianni Barrera, Roberto ^a   Gürke, Lorenz ^a   Heberer, Michael ^a   Banfi, Andrea ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Angiogenesis; Cellular therapy; Flow cytometry; Gene therapy; Skeletal muscle

Indexed keywords

CD8ALPHA ANTIGEN; VASCULOTROPIN;

ANGIOGENESIS; ANGIOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL POPULATION; CELL TRANSPLANTATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE THERAPY; MOUSE; MYOBLAST; NONHUMAN; STEM CELL; TISSUE ENGINEERING;

ANIMALS; ANTIGENS, CD8; CELL CULTURE TECHNIQUES; CELL SEPARATION; CELLS, CULTURED; FLOW CYTOMETRY; GENE THERAPY; GENETIC VECTORS; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PHYSIOLOGIC; STEM CELL TRANSPLANTATION; TRANSDUCTION, GENETIC; TRANSFECTION; TRANSGENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77950571103     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.291     Document Type: Article

References (40)

1. Lander AD. Morpheus unbound: reimagining the morphogen gradient. Cell 2007;128:245-256.
2. Banfi A, von Degenfeld G, Blau HM. Critical role of microenvironmental factors in angiogenesis. Curr Atheroscler Rep 2005;7:227-234. (Pubitemid 40796756)
3. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-660.
4. Gerhardt H, Golding M, Fruttiger M et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003;161:1163-1177. (Pubitemid 36870177)
5. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993;4:1317-1326. (Pubitemid 24045761)
6. Ozawa CR, Banfi A, Glazer NL et al. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest 2004;113:516-527. (Pubitemid 38542501)
7. von Degenfeld G, Banfi A, Springer ML et al. Microenvironmental VEGF distribution is critical for stable and functional vessel growth in ischemia. FASEB J 2006;20:2657-2659.
8. Tagawa M, Nakauchi H, Herzenberg LA et al. Formal proof that different-size Lyt-2 polypeptides arise from differential splicing and post-transcriptional regulation. Proc Natl Acad Sci USA 1986;83:3422-3426. (Pubitemid 16043049)
9. Rando TA, Blau HM. Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. J Cell Biol 1994;125:1275-1287.
10. Springer ML, Blau HM. High-efficiency retroviral infection of primary myoblasts. Somat Cell Mol Genet 1997;23:203-209. (Pubitemid 27444324)
11. Banfi A, Springer ML, Blau HM. Myoblast-mediated gene transfer for therapeutic angiogenesis. Methods Enzymol 2002;346:145-157. (Pubitemid 41103136)
12. Ghattas IR, Sanes JR, Majors JE. The encephalomyocarditis virus internal ribosome entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and in embryos. Mol Cell Biol 1991;11:5848-5859.
13. Mizuguchi H, Xu Z, Ishii-Watabe A et al. IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther 2000;1:376-382.
14. Sacco A, Doyonnas R, LaBarge MA et al. IGF-I increases bone marrow contribution to adult skeletal muscle and enhances the fusion of myelomonocytic precursors. J Cell Biol 2005;171:483-492. (Pubitemid 41586937)
15. Springer ML, Chen AS, Kraft PE et al. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol Cell 1998;2:549-558.
16. Drake CJ, Little CD. VEGF and vascular fusion: implications for normal and pathological vessels. J Histochem Cytochem 1999;47:1351-1356.
17. Gao GF, Jakobsen BK. Molecular interactions of coreceptor CD8 and MHC class I: the molecular basis for functional coordination with the T-cell receptor. Immunol Today 2000;21:630-636.
18. Ngoi SM, Chien AC, Lee CG. Exploiting internal ribosome entry sites in gene therapy vector design. Curr Gene Ther 2004;4:15-31.
19. Liu X, Constantinescu SN, Sun Y et al. Generation of mammalian cells stably expressing multiple genes at predetermined levels. Anal Biochem 2000;280:20-28. (Pubitemid 30210807)
20. Menasche P. Skeletal myoblasts and cardiac repair. J Mol Cell Cardiol 2007.
21. Montini E, Cesana D, Schmidt M et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 2009;119:964-975.
22. Baum C, Dullmann J, Li Z et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 2003;101:2099-2114. (Pubitemid 36302043)
23. Hacein-Bey-Abina S, von Kalle C, Schmidt M et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003;348:255-256. (Pubitemid 36077924)
24. Mavilio F, Pellegrini G, Ferrari S et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med 2006;12:1397-1402. (Pubitemid 44924498)
25. Rouwkema J, Rivron NC, van Blitterswijk CA. Vascularization in tissue engineering. Trends Biotechnol 2008;26:434-441.
26. Springer ML, Banfi A, Ye J et al. Localization of vascular response to VEGF is not dependent on heparin binding. FASEB J 2007;21:2074-2085. (Pubitemid 47026443)
27. Carmeliet P. VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat Med 2000;6:1102-1103.
28. Lee RJ, Springer ML, Blanco-Bose WE et al. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 2000;102:898-901.
29. Schwarz ER, Speakman MT, Patterson M et al. Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat-angiogenesis and angioma formation. J Am Coll Cardiol 2000;35:1323-1330. (Pubitemid 30206908)
30. Yla-Herttuala S, Rissanen TT, Vajanto I et al. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 2007;49:1015-1026. (Pubitemid 46349500)
31. Isner JM, Pieczek A, Schainfeld R et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996;348:370-374. (Pubitemid 26261511)
32. Kaigler D, Wang Z, Horger K et al. VEGF scaffolds enhance angiogenesis and bone regeneration in irradiated osseous defects. J Bone Miner Res 2006;21:735-744.
33. Ehrbar M, Metters A, Zammaretti P et al. Endothelial cell proliferation and progenitor maturation by fibrin-bound VEGF variants with differential susceptibilities to local cellular activity. J Control Release 2005;101:93-109. (Pubitemid 39600975)
34. Ehrbar M, Zeisberger SM, Raeber GP et al. The role of actively released fibrin-conjugated VEGF for VEGF receptor 2 gene activation and the enhancement of angiogenesis. Biomaterials 2008;29:1720-1729.
35. Dor Y, Djonov V, Abramovitch R et al. Conditional switching of VEGF provides new insights into adult neovascularization and proangiogenic therapy. EMBO J 2002;21:1939-1947. (Pubitemid 34437191)
36. Klabunde RE. Cardiovascular physiology concepts. Philadelphia: Lippincott Williams & Wilkins; 2005: ix, 235 p.
37. Ellis J. Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum Gene Ther 2005;16:1241-1246. (Pubitemid 41611651)
38. Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 2003;314:15-23.
39. Hellstrom M, Gerhardt H, Kalen M et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol 2001;153:543-553. (Pubitemid 34280141)
40. RayChaudhury A, D'Amore PA. Endothelial cell regulation by transforming growth factor-beta. J Cell Biochem 1991;47:224-229.